Insider Selling: Liam Ratcliffe Sells 1,673,172 Shares of Array BioPharma Stock (ARRY)
Array BioPharma (NASDAQ:ARRY) Director Liam Ratcliffe sold 1,673,172 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $6.08, for a total transaction of $10,172,885.76. The sale was disclosed in a document filed with the SEC, which is available at this link.
ARRY has been the subject of a number of recent research reports. Analysts at Jefferies Group raised their price target on shares of Array BioPharma (NASDAQ:ARRY) from $7.00 to $8.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of Array BioPharma (NASDAQ:ARRY) from $7.00 to $8.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann reiterated a “positive” rating on shares of Array BioPharma (NASDAQ:ARRY) in a research note to investors on Wednesday, July 24th.
Six research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $8.25.
Shares of Array BioPharma (NASDAQ:ARRY) traded down 0.33% during mid-day trading on Monday, hitting $6.10. The stock had a trading volume of 1,342,941 shares. Array BioPharma has a 52-week low of $3.25 and a 52-week high of $7.10. The stock has a 50-day moving average of $6.14 and a 200-day moving average of $5.4. The company’s market cap is $713.8 million.
Array BioPharma (NASDAQ:ARRY) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.07. The company had revenue of $25.40 million for the quarter, compared to the consensus estimate of $16.13 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was up 22.7% on a year-over-year basis. Analysts expect that Array BioPharma will post $-0.70 EPS for the current fiscal year.
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.